Psoriasis-Arthritis – Apremilast: Kein Zusatznutzen Ableitbar

Aktuelle Rheumatologie - Germany
doi 10.1055/s-0035-1563488
Full Text
Abstract

Available in full text

Categories
Rheumatology
Date
Authors

Unknown

Publisher

Georg Thieme Verlag KG

Related search

Utility of Apremilast in the Treatment of Psoriasis

International Journal of Basic & Clinical Pharmacology
2018English

Psoriasis and Arthritis

Annals of the Rheumatic Diseases
ImmunologyMolecular BiologyBiochemistryRheumatologyAllergyGenetics
1956English

Arthritis in Psoriasis.

Annals of the Rheumatic Diseases
ImmunologyMolecular BiologyBiochemistryRheumatologyAllergyGenetics
1981English

Comparison of Persistence Between Adults With Psoriasis Initiating Apremilast or Biologics

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2016English

Treatment Persistence in Psoriasis Patients Initiated on Apremilast, Oral Systemics, or Biologic Therapies

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

Apremilast: A Phosphodiesterase 4 Inhibitor for the Treatment of Psoriatic Arthritis

Rheumatology and Therapy
2014English

IQWiG Sieht Zusatznutzen

DNP - Der Neurologe und Psychiater
2016English

Psoriasis, Psoriatic Arthritis, and Thyroid Autoimmunity

Frontiers in Endocrinology
EndocrinologyMetabolismDiabetes
2017English

Which Psoriasis Patients Develop Psoriatic Arthritis?

Psoriasis Forum
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy